Mounjaro (Tirzepatide)

Tirzepatide is a dual agonist of the GIP and GLP‑1 receptors. Activation of these receptors enhances insulin secretion in a glucose‑dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite, collectively contributing to better glycaemic control.

The dosing regimen for Mounjaro is individualized by the prescribing healthcare professional. The prescriber determines the starting dose, titration schedule, and maintenance dose based on the patient’s clinical response, tolerability, and any concomitant therapies.

The safety of tirzepatide in pregnancy and lactation has not been established. It should be avoided unless the potential benefits justify the potential risks to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Mounjaro’s dual GIP/GLP‑1 receptor agonism offers a broader metabolic effect compared with single‑target GLP‑1 analogues, often resulting in greater HbA1c reduction and weight loss. However, individual response varies, and clinicians consider efficacy, safety profile, cost and patient preferences when selecting therapy.

Mounjaro must be stored refrigerated at 2‑8 °C, protected from light. Do not freeze or shake the vial. If a dose is not used within the recommended time after removal from refrigeration, follow the specific discard instructions provided by the manufacturer.

Mounjaro is supplied as an injectable solution for subcutaneous injection. It is typically administered once weekly in the abdomen, thigh or upper arm, using a pre‑filled pen or syringe as instructed by the prescribing clinician.

Serious risks include acute pancreatitis, severe hypersensitivity reactions, diabetic ketoacidosis (especially in insulin‑deficient patients), gallbladder disease, and marked hypoglycaemia when combined with insulin or sulfonylureas. Patients should be educated to recognize symptoms and seek immediate medical attention if they occur.

Mounjaro is contraindicated in individuals with a known hypersensitivity to tirzepatide or any excipients, and it should be avoided in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Caution is also advised for those with severe renal impairment.